New Filings At The EMA
Executive Summary
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
MSD, Astellas Keep Fingers Crossed For EU Fast-Track Status
The European Medicines Agency is this week considering applications from two companies seeking the coveted accelerated assessment review pathway for their new products.
EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018
In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.